MAPT and Alzheimer disease: The use of CSF biomarkers has enhanced our ability to detect the simultaneous presence of Aβ, tau protein, and neurofilament light chain (NFL), which are associated with AD, alongside markers of vascular damage, such as homocysteine and C-reactive protein (CRP).